AR062424A1 - Formulacion en aerosol para la inhalacion de beta - agonistas - Google Patents

Formulacion en aerosol para la inhalacion de beta - agonistas

Info

Publication number
AR062424A1
AR062424A1 ARP070103672A ARP070103672A AR062424A1 AR 062424 A1 AR062424 A1 AR 062424A1 AR P070103672 A ARP070103672 A AR P070103672A AR P070103672 A ARP070103672 A AR P070103672A AR 062424 A1 AR062424 A1 AR 062424A1
Authority
AR
Argentina
Prior art keywords
alkyl
enantiomers
halogen
means hydrogen
pharmacologically tolerable
Prior art date
Application number
ARP070103672A
Other languages
English (en)
Inventor
Michael Aven
Rainer Weitzel
Kristen Radau
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR062424A1 publication Critical patent/AR062424A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulacion para la inhalacion. Uso y kit. Reivindicacion 1: Formulacion medicamentosa que contiene como principio activo uno o varios compuestos de la formula general 1 en los que R1 significa hidrogeno, alquilo C1-4, O-alquilo C1-4 o halogeno; R2 significa hidrogeno, alquilo C1-4, O-alquilo C1-4 o halogeno; R3 significa hidrogeno, alquilo C1-4, O-alquilo C1-4, halogeno, OH, -O-alquiIen C1-4-COOH u O-alquilen C1-4-COO-alquilo C1-4; X significa un anion de carga negativa simple o multiple, con preferencia un anion de carga negativa simple o multiple seleccionado del grupo compuesto por cloruro, bromuro, yoduro, sulfato fosfato, metansulfonato, nitrato, maleato, acetato, benzoato, citrato, salicilato, trifluoroacetato, fumarato, tartrato, oxalato, succinato, benzoato y p-toluensulfonato, eventualmente en forma de sus tautomeros, enantiomeros, mezclas de los enantiomeros, racematos, solvatos o hidratos: un principio activo 2 seleccionado del grupo consistente en budesonida, beclometasona, fluticasona, ciclesonida o un metabolito del mismo, eventualmente en forma de sus tautomeros, enantiomeros, mezclas de los enantiomeros, racematos, solvatos o hidratos; al menos un ácido farmacologicamente tolerable o un sistema tampon farmacologicamente tolerable, eventualmente otros coadyuvantes farmacologicamente tolerables, así como en calidad de disolvente agua, etanol o una mezcla de agua y etanol.
ARP070103672A 2006-08-18 2007-08-17 Formulacion en aerosol para la inhalacion de beta - agonistas AR062424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119129 2006-08-18
EP07101128 2007-01-25

Publications (1)

Publication Number Publication Date
AR062424A1 true AR062424A1 (es) 2008-11-05

Family

ID=39082381

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103672A AR062424A1 (es) 2006-08-18 2007-08-17 Formulacion en aerosol para la inhalacion de beta - agonistas

Country Status (17)

Country Link
US (1) US20080041370A1 (es)
EP (1) EP2054034A2 (es)
JP (1) JP2010501021A (es)
KR (1) KR20090040922A (es)
AR (1) AR062424A1 (es)
AU (1) AU2007285746A1 (es)
BR (1) BRPI0715692A2 (es)
CA (1) CA2660480A1 (es)
CO (1) CO6150123A2 (es)
EA (1) EA200900267A1 (es)
IL (1) IL197024A0 (es)
MX (1) MX2009001553A (es)
NO (1) NO20090410L (es)
PE (1) PE20080607A1 (es)
TW (1) TW200817010A (es)
UY (1) UY30543A1 (es)
WO (1) WO2008020056A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
CA2619402C (en) 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Method for producing betamimetics
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
WO2014016548A2 (en) 2012-07-27 2014-01-30 Cipla Limited Pharmaceutical composition
WO2014096116A1 (en) 2012-12-21 2014-06-26 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical formulation comprising ciclesonide
ES2693779T3 (es) * 2012-12-21 2018-12-13 Boehringer Ingelheim Vetmedica Gmbh Ciclesonida para el tratamiento de enfermedades de las vías respiratorias en caballos
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
HUE051527T2 (hu) 2014-06-18 2021-03-01 Boehringer Ingelheim Vetmedica Gmbh Muszkarin-antagonisták és kombinációik légúti betegség lovakban történõ kezelésére
JP7189766B2 (ja) 2015-10-09 2022-12-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング マイクロ構造コンポーネントのコーティング方法
WO2021211850A1 (en) * 2020-04-16 2021-10-21 Anovent Pharmaceutical(U.S.)., Llc Inhalable formulation of a solution containing olodaterol
CN115397417A (zh) * 2020-04-16 2022-11-25 广州谷森制药有限公司 含有噻托溴铵和奥达特罗的可吸入溶液制剂
CN115835885A (zh) * 2020-06-23 2023-03-21 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
ES2380370T3 (es) * 2004-04-22 2012-05-11 Boehringer Ingelheim International Gmbh Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten

Also Published As

Publication number Publication date
PE20080607A1 (es) 2008-07-17
JP2010501021A (ja) 2010-01-14
TW200817010A (en) 2008-04-16
AU2007285746A1 (en) 2008-02-21
EP2054034A2 (de) 2009-05-06
NO20090410L (no) 2009-03-02
CA2660480A1 (en) 2008-02-21
WO2008020056A2 (de) 2008-02-21
IL197024A0 (en) 2009-11-18
CO6150123A2 (es) 2010-04-20
US20080041370A1 (en) 2008-02-21
BRPI0715692A2 (pt) 2013-08-06
EA200900267A1 (ru) 2009-08-28
UY30543A1 (es) 2008-03-31
MX2009001553A (es) 2009-04-17
WO2008020056A3 (de) 2008-09-12
KR20090040922A (ko) 2009-04-27

Similar Documents

Publication Publication Date Title
AR062424A1 (es) Formulacion en aerosol para la inhalacion de beta - agonistas
CO6170341A2 (es) Formulacion de aerosol que contiene derivados de benzoxazin-3onas
AR058082A1 (es) Formulacion en aerosol para la inhalacion de beta- agonistas
AR049096A1 (es) Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas
HRP20080140T3 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
AR070936A1 (es) 1,2,4 -triazoles trisustituidos
MY150519A (en) Imidazoquinolines with immuno-modulating properties
AR049650A1 (es) Derivados 5-aril-1h-pirrol[2,3-b]piridin-3-carboxamida o acido 5-aril-1h-pirrol[2,3-b]piridin-3-carboxilico
MX2021000375A (es) Degradadores selectivos del receptor de estrogeno.
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
BR112012013511A2 (pt) derivados de difenil-pirazolopiridinas, sua preparação e seu uso como não moduladores do receptor nuclear
UY30736A1 (es) Compuestos quimicos 537
MX2010003698A (es) Compuestos de [3,2-c]pirazol esteroides con actividad glucocorticoide.
AR072802A1 (es) Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios.
JP2015522025A5 (es)
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
NO20065885L (no) Steroide prolegemidler med androgen virkning
AR062477A1 (es) Formulacion aerosol para la inhalacion de beta - agonistas
AR062476A1 (es) Beta - agonistas enentiomericamente puros, procedimientos para su preparacion y su uso como medicamentos
AR039275A1 (es) Medicamento que contiene esteroides y un nuevo anticolinergico
AR055597A1 (es) Uso de sales de tiotripio en el tratamiento del asma persistente severa
AR059836A1 (es) Beta-agonistas enantiomericamente puros, y su uso como medicamentos
UY28457A1 (es) Nueva composición
AR038764A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio

Legal Events

Date Code Title Description
FB Suspension of granting procedure